Cue Biopharma (NASDAQ:CUE) Upgraded by Zacks Investment Research to Strong-Buy

Posted by on Nov 16th, 2019 // Comments off

Zacks Investment Research upgraded shares of Cue Biopharma (NASDAQ:CUE) from a hold rating to a strong-buy rating in a research report sent to investors on Friday, Zacks.com reports. Zacks Investment Research currently has $10.00 price objective on the stock.

According to Zacks, “Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts. “

CUE has been the topic of a number of other reports. Robert W. Baird started coverage on shares of Cue Biopharma in a research note on Thursday, July 25th. They issued an outperform rating and a $13.00 price objective on the stock. ValuEngine lowered shares of Cue Biopharma from a hold rating to a sell rating in a research report on Wednesday.

NASDAQ:CUE traded down $0.19 during mid-day trading on Friday, hitting $8.80. The stock had a trading volume of 37,900 shares, compared to its average volume of 52,565. The company’s 50 day simple moving average is $8.11 and its 200 day simple moving average is $8.06. The stock has a market cap of $201.89 million, a price-to-earnings ratio of -4.54 and a beta of 1.21. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.17 and a current ratio of 3.17. Cue Biopharma has a twelve month low of $4.16 and a twelve month high of $9.94.

A number of hedge funds have recently added to or reduced their stakes in CUE. BlackRock Inc. lifted its holdings in Cue Biopharma by 21.3% in the second quarter. BlackRock Inc. now owns 1,148,126 shares of the company’s stock valued at $10,321,000 after buying an additional 201,986 shares during the period. Vanguard Group Inc. increased its stake in Cue Biopharma by 33.8% in the second quarter. Vanguard Group Inc. now owns 612,151 shares of the company’s stock valued at $5,504,000 after purchasing an additional 154,639 shares in the last quarter. Rock Creek Group LP bought a new stake in Cue Biopharma in the second quarter valued at $447,000. Strs Ohio increased its stake in Cue Biopharma by 88.0% in the third quarter. Strs Ohio now owns 28,200 shares of the company’s stock valued at $237,000 after purchasing an additional 13,200 shares in the last quarter. Finally, Sigma Planning Corp increased its stake in Cue Biopharma by 25.9% in the third quarter. Sigma Planning Corp now owns 60,210 shares of the company’s stock valued at $508,000 after purchasing an additional 12,405 shares in the last quarter. Institutional investors and hedge funds own 20.09% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.

Recommended Story: The risks of owning bonds

Get a free copy of the Zacks research report on Cue Biopharma (CUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.